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However, in the absence of head-to-head treatment com-
parison, conﬁdence in these estimates is low. Future
head-to-head treatment comparison trails and compara-
tive effectiveness observational studies in a homogenous
cohort are warranted.
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SIRS, We thank Singh et al. for their thoughtful letter.1
This highlights three aspects of our manuscript that we
believe deserve further discussion.2
First, although we agree that inclusion of vedolizumab,
an anti-integrin therapeutic, is a potential option, we
elected to focus on comparing anti-tumour necrosis
factor (anti-TNF) agents to limit issues of clinical and
biologic heterogeneity. Second, we found the deﬁnitions
and reporting of prior anti-TNF exposure to be inconsis-
tent between studies (e.g. prior anti-TNF permitted but
data not reported, variable washout lengths). While we
documented reported anti-TNF exposure in Table 1, we
were unable to meaningfully analyse patients by prior
anti-TNF exposure. Finally, the authors raise concerns
over using a clinical endpoint (Mayo score or ulcerative
colitis symptom score) as the primary outcome mea-
sure in our meta-analysis. Although we agree that
objective measures are preferred, the clinical trials
available for inclusion in our network meta-analysis
were designed and powered based on clinical activity
indices.
The results of Singh et al.’s work reported similar
ﬁndings to our analysis – that available clinical trial data
do not demonstrate signiﬁcant differences in efﬁcacy
between anti-TNF agents, and potentially vedolizumab.
This discussion points out important limitations of the
available data, highlighting the need for objective and
reproducible measures of disease activity in ulcerative
colitis clinical trials. Head-to-head studies are needed to
better understand the comparative efﬁcacy of therapies
for ulcerative colitis.
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SIRS, We have read with interest some recent reports
about transient elastography (TE) published in the jour-
nal1, 2 and we would like to comment our results regard-
ing the comparison of a new FibroScan device with the
original FS502. Despite signiﬁcant advantages, FibroScan
(Echosens, Paris, France) has some drawbacks like high
acquisition and maintenance costs that might have lead
to refusal of many hospitals to incorporate TE in the
routine evaluation of patients with chronic liver diseases.
If the new, and cheaper, device recently commercialised
(FS402) is equivalent to conventional one (FS502), it
could translate into a greater generalisation of TE.
To evaluate whether these two devices could be con-
sidered equivalent, we perform a cross-sectional prospec-
tive study in our clinic. All consecutive HCV infected
patients attending our unit had consecutive liver stiffness
measurement with FS502 and FS402, on the same area
and by the same observer. Agreement between FS502
and FS402 was characterised using the Kappa index3 for
four cut-offs values: <7.2 kPa (F1), 7.2–12.4 kPa (F2–F3)
and >12.4 kPa (F4)4 and for signiﬁcant ﬁbrosis (9 kPa).5
We included 101 patients, mostly men (72 men vs. 29
women) and with a mean BMI: of 25.2  0.85 kg/m2.
Concordance between FS502 and FS402 is shown in
Figure 1.
No statistically signiﬁcant differences were obtained for
F1 and F4 measurements, with strong correlation [n = 52;
rho Spearman (rs): 0.827; P = 0.01 and n = 28; rs: 0.935;
P = 0.001 respectively] and substantial agreement between
both devices (Kappa 0.781; P < 0.001 and 0.923;
P < 0.001, respectively). For F2–F3 stages, there was a sig-
niﬁcant difference between both devices (median 9.4 vs. 8
for FS502 and FS402, respectively; P = 0.024). There was
also a strong correlation substantial agreement between
both devices, although to a lesser extent (n = 35; rs: 0.737;
P = 0.01 and Kappa 0.654; P < 0.001).
Regarding presence or absence of signiﬁcant ﬁbrosis,5
we found a very strong correlation (n = 101; rs: 0.861;
P < 0.001) and an almost perfect agreement between
FS502 and FS402 (Kappa: 0.856 P < 0.001).
Globally, although FS402 might underestimate the
degree of ﬁbrosis, as median values are statistically sig-
niﬁcantly higher with FS502, when stratifying for pres-
ence or absence of ﬁbrosis, we found almost perfect
agreement and a very strong correlation, suggesting that
these differences, although statistically signiﬁcant, are
clinically irrelevant and, from a clinical interpretation of
results, both devices can be considered as equivalent.
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Figure 1 | Concordance of classiﬁcation of ﬁbrosis using
FS502 and FS402 devices, according to ﬁbrosis stages.4
Columns represent percentages of concordance.
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